Dianthus Therapeutics

Compare

401 Followers

DNTH Stock Chart & Stats

$33.82

$0.37(1.44%)

At close: Jan 08 4:00 PM EST

$33.82

$0.37(1.44%)

Day’s Range― - ―

52-Week Range$13.37 - $40.16

Previous CloseN/A

Volume29.07K

Average Volume (3M)1.00M

Market Cap

$1.34B

Enterprise Value$411.31M

Total Cash (Recent Filing)$257.39M

Total Debt (Recent Filing)$1.33M

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Nov 06, 2025

EPS Estimate

-0.88

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.88

Shares Outstanding39,816,223

10 Day Avg. Volume588,847

30 Day Avg. Volume1,003,841

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.31

Enterprise Value/Revenue84.74

Enterprise Value/Gross Profit86.50

Enterprise Value/Ebitda-3.17

Forecast

1Y Price Target

$67.85

Price Target Upside100.62% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

Bulls Say, Bears Say

Bulls Say

Acquisition And Intellectual PropertyDianthus announced an agreement to acquire global rights for DNTH212, ensuring long-term intellectual property protection with composition of matter protection expected to expire no earlier than 2044.

Clinical Trial SuccessDianthus released positive clinical data from its Phase II MaGic study, showing claseprubart led to rapid and clinically meaningful symptom improvement in generalized myasthenia gravis patients.

Safety ProfileClaseprubart demonstrated a clean safety profile without evidence of autoimmune activation or infections, which is a significant advantage over other complement inhibitors with boxed warnings.

Bears Say

Dose Selection ConcernsThe muted reaction in the stock is due to questions on the selection of doses for Phase III and anti-nuclear antibody cases.

Short InterestShort interest in the company is relatively high at 17.1%, indicating potential skepticism from some investors.

Stock Reversal IssuesConfusion on ANA titers led to a stock reversal, noted as an issue in the last 30 minutes of trading.

Dianthus Therapeutics News

Dianthus enters exclusive license agreement with Leads Biolabs for DNTH212

Dianthus (DNTH) Therapeutics entered into an exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212, a first and...

16d ago

DNTH

3 Best Stocks to Buy Now, 10/14/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

18d ago

NOW

ARES

Dianthus initiated with a Buy at Truist

Truist analyst Danielle Brill initiated coverage of Dianthus (DNTH) with a Buy rating and $56 price target The...

18d ago

DNTH

Promising Clinical Data and Strategic Plans Position Dianthus Therapeutics as an Attractive Investment Opportunity

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Dianthus Therapeutics. The associated price target...

2d ago

DNTH

Dianthus Therapeutics Advances CIDP Treatment with DNTH103 Study

Dianthus Therapeutics, Inc. (($DNTH)) announced an update on their ongoing clinical study. Study Overview: Dianthus Therapeutics, Inc. is...

4d ago

DNTH

Dianthus Therapeutics Advances Phase 2 Study of DNTH103 for Neuropathy

Dianthus Therapeutics, Inc. (($DNTH)) announced an update on their ongoing clinical study. Study Overview: Dianthus Therapeutics, Inc. is...

4d ago

DNTH

Dianthus Therapeutics: Strategic Positioning and Innovative Pipeline Justify Buy Rating

William Blair analyst Myles Minter has reiterated their bullish stance on DNTH stock, giving a Buy rating today....

15d ago

DNTH

Dianthus Therapeutics’ Strategic Moves and Pipeline Potential Justify Buy Rating

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Dianthus Therapeutics. The associated price target...

15d ago

DNTH

Dianthus Therapeutics Signs License Agreement with Nanjing Leads

Dianthus Therapeutics ( ($DNTH) ) has shared an announcement. On October 16, 2025, Dianthus Therapeutics entered into a...

16d ago

DNTH

Short Report: Dave & Busters bears boost exposure

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

1M ago

AAOI

DNTH

3 Best Stocks to Buy Now, 9/17/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1M ago

DNTH

Dianthus initiated with a Buy at Clear Street

Clear Street analyst Bill Maughan initiated coverage of Dianthus (DNTH) with a Buy rating and $100 price target...

2M ago

DNTH

Dianthus price target raised to $65 from $52 at Stifel

Stifel analyst Alex Thompson raised the firm’s price target on Dianthus (DNTH) to $65 from $52 and keeps...

2M ago

DNTH

Dianthus price target raised to $44 from $42 at Wedbush

Wedbush raised the firm’s price target on Dianthus (DNTH) to $44 from $42 and keeps an Outperform rating...

2M ago

DNTH

DNTH FAQ

What was Dianthus Therapeutics’s price range in the past 12 months?

Dianthus Therapeutics lowest stock price was $13.37 and its highest was $40.16 in the past 12 months.

What is Dianthus Therapeutics’s market cap?

Dianthus Therapeutics’s market cap is $1.34B.

When is Dianthus Therapeutics’s upcoming earnings report date?

Dianthus Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 5 days.

How were Dianthus Therapeutics’s earnings last quarter?

Dianthus Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.872 by -$0.008.

Is Dianthus Therapeutics overvalued?

According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dianthus Therapeutics pay dividends?

Dianthus Therapeutics does not currently pay dividends.

What is Dianthus Therapeutics’s EPS estimate?

Dianthus Therapeutics’s EPS estimate is -0.88.

How many shares outstanding does Dianthus Therapeutics have?

Dianthus Therapeutics has 39,816,223 shares outstanding.

What happened to Dianthus Therapeutics’s price movement after its last earnings report?

Dianthus Therapeutics reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.872. Following the earnings report the stock price went down -2.037%.

Which hedge fund is a major shareholder of Dianthus Therapeutics?

Currently, no hedge funds are holding shares in DNTH

Dianthus Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-34.71%

Trailing 12-Months

Asset Growth

-11.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dianthus Therapeutics

Dianthus Therapeutics (DNTH) is a biotechnology company focused on developing innovative therapies for serious autoimmune diseases. The company specializes in the discovery and commercialization of monoclonal antibodies and other biologics that target specific immune pathways. Dianthus is committed to addressing unmet medical needs and enhancing patient care through its advanced therapeutic solutions in the biopharmaceutical sector.

Dianthus Therapeutics (DNTH) Earnings & Revenues

Historic Earnings Reports

DNTH Stock 12 Month Forecast

Average Price Target

$67.85

▲(100.62% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","58":"$58","101":"$101","36.5":"$36.5","79.5":"$79.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,36.5,58,79.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.93,43.62769230769231,48.325384615384614,53.02307692307693,57.720769230769235,62.41846153846154,67.11615384615385,71.81384615384616,76.51153846153846,81.20923076923077,85.90692307692308,90.60461538461539,95.30230769230769,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.93,41.15461538461538,43.379230769230766,45.60384615384615,47.82846153846154,50.053076923076915,52.277692307692305,54.50230769230769,56.72692307692307,58.951538461538455,61.17615384615384,63.40076923076923,65.6253846153846,{"y":67.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.93,39.012307692307694,39.09461538461539,39.176923076923075,39.25923076923077,39.34153846153846,39.423846153846156,39.50615384615384,39.58846153846154,39.67076923076923,39.753076923076925,39.83538461538461,39.917692307692306,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.88,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >